Company
Nutromics
Nutromics builds a wearable "lab-on-a-patch" that uses DNA-aptamer biosensors on a microneedle array to measure molecules in interstitial fluid continuously, rather than at single points via blood draws. The lead indication is therapeutic drug monitoring of vancomycin in intensive care sepsis patients, an antibiotic with a narrow therapeutic window that is hard to dose correctly. The company has also shown simultaneous real-time measurement of two antibiotics (vancomycin and tobramycin) on one device in animal models, and is working on a sepsis management patch. The longevity relevance is infrastructural rather than an intervention: it is a platform for continuous biomarker tracking that could extend beyond drugs to other dynamic analytes, shifting diagnostics from episodic lab tests to trend data. No product has regulatory approval anywhere; the company states FDA clearance for vancomycin monitoring is targeted from 2028, so nothing is in clinical use today.
At a glance
- Listing
- Private, not listed
- Category
- Diagnostics
- Headquarters
- Brunswick, Victoria, Australia (420 Victoria Street, Brunswick VIC 3056)
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- Diagnostics
- Market
- Australia
- Recent inflection
- April 2026: Nutromics was awarded about A$3m within a A$11.2m Cooperative Research Centres Projects consortium to develop a sepsis management patch, and appointed Tom Prescott as Board Chair ahead of a planned 2027 commercial launch (company media page, nutromics.com/media). Earlier, in October 2025 it presented what it described as the first real-time in vivo multiplexed data measuring vancomycin and tobramycin simultaneously on one device at IATDMCT.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | Unlisted |
| Ticker | None |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Private |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Brunswick, Victoria, Australia (420 Victoria Street, Brunswick VIC 3056)
- Website
- www.nutromics.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
April 2026: Nutromics was awarded about A$3m within a A$11.2m Cooperative Research Centres Projects consortium to develop a sepsis management patch, and appointed Tom Prescott as Board Chair ahead of a planned 2027 commercial launch (company media page, nutromics.com/media). Earlier, in October 2025 it presented what it described as the first real-time in vivo multiplexed data measuring vancomycin and tobramycin simultaneously on one device at IATDMCT.
Common questions
- Why does variis track Nutromics?
- Nutromics builds a wearable "lab-on-a-patch" that uses DNA-aptamer biosensors on a microneedle array to measure molecules in interstitial fluid continuously, rather than at single points via blood draws. The lead indication is therapeutic drug monitoring of vancomycin in intensive care sepsis patients, an antibiotic with a narrow therapeutic window that is hard to dose correctly. The company has also shown simultaneous real-time measurement of two antibiotics (vancomycin and tobramycin) on one device in animal models, and is working on a sepsis management patch. The longevity relevance is infrastructural rather than an intervention: it is a platform for continuous biomarker tracking that could extend beyond drugs to other dynamic analytes, shifting diagnostics from episodic lab tests to trend data. No product has regulatory approval anywhere; the company states FDA clearance for vancomycin monitoring is targeted from 2028, so nothing is in clinical use today.
- Is Nutromics publicly listed?
- variis has no ticker on file for Nutromics, so it is tracked as private or unlisted. Absence of a ticker on this record is not a statement that no listing exists anywhere.
- Where is Nutromics based?
- Brunswick, Victoria, Australia (420 Victoria Street, Brunswick VIC 3056)
- Is Nutromics still trading?
- Nutromics is recorded as private.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Nutromics: continuous molecular monitoring lab-on-a-patch (HQ address, technology, no regulatory approval) · Nutromics
- Nutromics media page: April 2026 CRC-P sepsis patch funding, board chair appointment, multiplexing and vancomycin trial milestones · Nutromics
- Aussie start-up Nutromics behind 'lab on a patch' that replaces blood tests raises $7.5m (4 September 2025) · Stockhead
Every entity profile on variis is sourced. Not investment advice.